These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29923323)

  • 21. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
    Bethel MA; Sourij H; Stevens SR; Hannan K; Lokhnygina Y; Adler AI; Peterson ED; Holman RR; Lopes RD
    Cardiovasc Diabetol; 2023 Mar; 22(1):72. PubMed ID: 36978066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Green JB; Everett BM; Ghosh A; Younes N; Krause-Steinrauf H; Barzilay J; Desouza C; Inzucchi SE; Pokharel Y; Schade D; Scrymgeour A; Tan MH; Utzschneider KM; Mudaliar S;
    Circulation; 2024 Mar; 149(13):993-1003. PubMed ID: 38344820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
    Engel SS; Suryawanshi S; Stevens SR; Josse RG; Cornel JH; Jakuboniene N; Riefflin A; Tankova T; Wainstein J; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study.
    Yang TY; Liaw YP; Huang JY; Chang HR; Chang KW; Ueng KC
    Acta Diabetol; 2016 Jun; 53(3):461-8. PubMed ID: 26687195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
    Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
    JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Bhatt AS; Luo N; Solomon N; Pagidipati NJ; Ambrosio G; Green JB; McGuire DK; Standl E; Cornel JH; Halvorsen S; Lopes RD; White HD; Holman RR; Peterson ED; Mentz RJ;
    Am Heart J; 2019 Dec; 218():57-65. PubMed ID: 31707329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Green JB; Merrill P; Lokhnygina Y; Mentz RJ; Alfredsson J; Holman RR;
    Diabetes Obes Metab; 2023 Jun; 25(6):1473-1484. PubMed ID: 36700460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
    Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
    Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
    Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
    Charytan DM; Solomon SD; Ivanovich P; Remuzzi G; Cooper ME; McGill JB; Parving HH; Parfrey P; Singh AK; Burdmann EA; Levey AS; Eckardt KU; McMurray JJV; Weinrauch LA; Liu J; Claggett B; Lewis EF; Pfeffer MA
    Diabetes Obes Metab; 2019 May; 21(5):1199-1208. PubMed ID: 30672083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
    Hirshberg B; Katz A
    Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON study.
    Rådholm K; Chalmers J; Ohkuma T; Peters S; Poulter N; Hamet P; Harrap S; Woodward M
    Diabetes Obes Metab; 2018 Aug; 20(8):1903-1910. PubMed ID: 29603537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
    Marx N; McGuire DK; Perkovic V; Woerle HJ; Broedl UC; von Eynatten M; George JT; Rosenstock J
    Diabetes Care; 2017 Sep; 40(9):1144-1151. PubMed ID: 28830955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.